Pascal and Francis Bibliographic Databases

Help

Export

Selection :

Permanent link
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22530306

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)

Author
OLIN, Jason T1 ; BHATNAGAR, Vinod2 ; REYES, Patricio3 ; KOUMARAS, Barbara1 ; XIANGYI MENG1 ; BRANNAN, Stephen4
[1] Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
[2] Center for Clinical Trials and Research, Inc., Venice, FL, United States
[3] Barrow Neurological Institute, Phoenix, AZ, United States
[4] Takeda Pharmaceuticals North America, (formerly Novartis Pharmaceuticals Corporation), Deerfield, IL, United States
Source

International journal of geriatric psychiatry. 2010, Vol 25, Num 4, pp 419-426, 8 p ; ref : 1/4 p

ISSN
0885-6230
Scientific domain
Cognition; Psychology, psychopathology, psychiatry
Publisher
Psychology Press, Hove
Publication country
United Kingdom
Document type
Article
Language
English
Author keyword
Alzheimer's disease cholinesterase inhibitor dementia memantine rivastigmine tolerability
Keyword (fr)
Antialzheimer Anticholinestérasique Antiparkinsonien Association médicamenteuse Capsule Démence d'Alzheimer Efficacité traitement Environnement social Essai clinique Etude longitudinale Forme pharmaceutique Mémantine Nootrope Personne âgée Pharmacothérapie Psychotrope Rivastigmine Santé mentale Santé publique Toxicité Essai ouvert Essai thérapeutique Etats-Unis Acetylcholinesterase Antagoniste Carboxylic ester hydrolases Dérivé de l'amantadine Enzyme Esterases Homme Hydrolases Inhibiteur enzyme Maladie dégénérative Pathologie de l'encéphale Pathologie du système nerveux central Pathologie du système nerveux Récepteur NMDA Récepteur glutamate Traitement Amérique du Nord Amérique
Keyword (en)
Antialzheimer agent Anticholinesterase agent Antiparkinson agent Drug combination Capsule Alzheimer disease Treatment efficiency Social environment Clinical trial Follow up study Dosage form Memantine Nootropic agent Elderly Pharmacotherapy Psychotropic Rivastigmine Mental health Public health Toxicity United States Acetylcholinesterase Antagonist Carboxylic ester hydrolases Amantadine derivatives Enzyme Esterases Human Hydrolases Enzyme inhibitor Degenerative disease Cerebral disorder Central nervous system disease Nervous system diseases NMDA receptor Glutamate receptor Treatment North America America
Keyword (es)
Antialzheimer Anticolinesterasa agente Antiparkinsoniano Asociación medicamentosa Cápsula Demencia Alzheimer Eficacia tratamiento Contexto social Ensayo clínico Estudio longitudinal Forma farmacéutica Memantina Nootropo Anciano Farmacoterapia Psicotropo Rivastigmina Salud mental Salud pública Toxicidad Estados Unidos Acetylcholinesterase Antagonista Carboxylic ester hydrolases Amantadina derivada Enzima Esterases Hombre Hydrolases Inhibidor enzima Enfermedad degenerativa Encéfalo patología Sistema nervosio central patología Sistema nervioso patología Receptor NMDA Receptor glutámato Tratamiento America del norte America
Classification
Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02B Neuropharmacology / 002B02B02 Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)

Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02U Drug toxicity and drugs side effects treatment / 002B02U10 Miscellaneous (drug allergy, mutagens, teratogens...)

Francis
770 Psychology. Psychoanalysis. Psychiatry / 770-E Psychopharmacology / 770-E02 Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer…

Discipline
Drugs toxicity and drug intoxications Pharmacological treatments Psychopathology. Psychiatry. Clinical psychology Toxicology
Origin
Inist-CNRS
Database
FRANCIS ; PASCAL
INIST identifier
22530306

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS

Access to the document

Searching the Web